Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Purpose-built for physicians Human, exendin-based GLP-1 receptor agonists similarly reduce CV, renal risk in diabetes A pooled study assessing trials of eight GLP-1 receptor agonists showed all reduce risk for a combined endpoint of major adverse cardiovascular events, regardless of structural homology to human GLP-1, as well as individual CV components
ISBN 978-3-11-070284-2
But context matters
Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes
US$ 22.87
US$ 23.99
US$ 20.21
US$ 23.83
US$ 21.25
US$ 25.85
